October 14, 2024
Sector earnings or LPS (loss-per-share) season is just ahead …
Pre-open indications: 3 Positive and 4 Negative Indications
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
Never leave an investor uninform
October 15, 2024
LPS (loss-per-share) releases will present challenges to share pricing with outcomes included
2 to report ... so far:
Sage Therapeutics (SAGE) 10/29 Tuesday
MiMedx (MDXG) 10/30 Wednesday
October 15, 2024
Sector tuned positive late in the session after a neutral start and with a negative dive then an out-of-the-blue positive close
As Q3 earnings season is about to begin, uncertainty looms, raising questions about its impact on share pricing performance
Never leave an investor uninformed!
The week in review
October 15, 2024
LPS (loss-per-share) releases will present challenges to share pricing with outcomes included 2 to report ... so far: Sage Therapeutics (SAGE) 10/29 Tuesday MiMedx (MDXG) 10/30 Wednesday
October 3, 2024
Called “Monetization Financing with DRI Healthcare Trust” as access to capital markets is shaky EDIT sold certain future license fees and other payments owed under its Cas9 license agreement with Vertex Pharmaceuticals (VRTX)to a wholly-owned subsidiary of DRI Healthcare Trust (DRI) for an upfront cash payment of $57 million. EDIT closed down -$0.02 with only a +$0.06 or +1.87% aftermarket indication
September 10, 2024
Priced at $43.50 of 11.5 M shares IONS closed up +$1.44 or +3.07 M to $48.03 with a negative -$5.94 to $42.39 on Tuesday Check-out debt versus cash (below) Morgan Stanley and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering
© 2024 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
